Pages that link to "Q47288123"
Jump to navigation
Jump to search
The following pages link to Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study (Q47288123):
Displaying 50 items.
- Pharmacotherapies for obesity: past, current, and future therapies (Q21296814) (← links)
- Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies (Q24650977) (← links)
- Obesity pharmacotherapy: current perspectives and future directions (Q26828559) (← links)
- Off-label drugs for weight management (Q33806796) (← links)
- Gut hormones such as amylin and GLP-1 in the control of eating and energy expenditure (Q33838133) (← links)
- Pramlintide and the treatment of diabetes: a review of the data since its introduction (Q33896433) (← links)
- Efficacy and harms of the hypoglycemic agent pramlintide in diabetes mellitus (Q34287711) (← links)
- New pharmacological perspectives for the leptin receptor in the treatment of obesity (Q34330557) (← links)
- Present and Future: Pharmacologic Treatment of Obesity (Q34572487) (← links)
- Plasma Amylin and Cognition in Diabetes in the Absence and the Presence of Insulin Treatment (Q35149972) (← links)
- GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities (Q36153247) (← links)
- The effect of meal frequency in a reduced-energy regimen on the gastrointestinal and appetite hormones in patients with type 2 diabetes: A randomised crossover study. (Q36331824) (← links)
- Pharmacotherapy for childhood obesity: present and future prospects (Q36468087) (← links)
- Prevention and treatment of type 2 diabetes: current role of lifestyle, natural product, and pharmacological interventions (Q36740436) (← links)
- Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity (Q36842060) (← links)
- Gut hormones as potential new targets for appetite regulation and the treatment of obesity (Q37057996) (← links)
- Leptin does not directly regulate the pancreatic hormones amylin and pancreatic polypeptide: interventional studies in humans (Q37365646) (← links)
- Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy (Q37368085) (← links)
- Emerging drugs for obesity therapy. (Q37494328) (← links)
- Amylin/leptin synergy is absent in extreme obesity and not restored by calorie restriction-induced weight loss in rats (Q37539627) (← links)
- The role of pramlintide for weight loss (Q37694145) (← links)
- Adjunct therapy for type 1 diabetes mellitus (Q37734219) (← links)
- The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis (Q37825605) (← links)
- Pharmacologic management of obesity (Q37947165) (← links)
- Approaches to the pharmacological treatment of obesity (Q37960073) (← links)
- Advances in medical therapy for weight loss and the weight-centric management of type 2 diabetes mellitus. (Q37960391) (← links)
- Control of energy homeostasis by amylin (Q37970941) (← links)
- The interaction of amylin with other hormones in the control of eating (Q38031993) (← links)
- Peripheral signalling involved in energy homeostasis control (Q38061797) (← links)
- Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of The Obesity Society and the American Society of Hypertension (Q38071133) (← links)
- Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment--a position paper of the The Obesity Society and The American Society of Hypertension (Q38080812) (← links)
- The central question of type 2 diabetes (Q38162978) (← links)
- Amylin and its analogs: a friend or foe for the treatment of Alzheimer's disease? (Q38239648) (← links)
- Role of Amylin in Type 1 and Type 2 Diabetes (Q38596374) (← links)
- Amylin-mediated control of glycemia, energy balance, and cognition (Q38753342) (← links)
- Renaissance of leptin for obesity therapy (Q38777443) (← links)
- A novel dual amylin and calcitonin receptor agonist, KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference (Q39008520) (← links)
- Amylin (Q39293507) (← links)
- Amylin and its G-protein-coupled receptor: A probable pathological process and drug target for Alzheimer's disease (Q39320824) (← links)
- Noradrenergic neurons of the area postrema mediate amylin's hypophagic action (Q43016753) (← links)
- Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial (Q43186384) (← links)
- Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight (Q43236384) (← links)
- Food intake and meal pattern in IAPP knockout mice with and without infusion of exogenous IAPP. (Q43866304) (← links)
- Optimizing diabetes treatment using an amylin analogue (Q44989550) (← links)
- Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats (Q46535152) (← links)
- Differential responses of circulating amylin to high-fat vs. high-carbohydrate meal in healthy men. (Q46887483) (← links)
- Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptide (Q46985676) (← links)
- Modeling energy intake and body weight effects of a long-acting amylin analogue (Q47175680) (← links)
- Amylin - Its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity. (Q47371506) (← links)
- Optimization of tolerability and efficacy of the novel dual amylin and calcitonin receptor agonist KBP-089 through dose escalation and combination with a GLP-1 analog (Q48130202) (← links)